Objective To investigate the relationship between thyroid stimulating hormone (TSH) and the blood lipid level in patients with subclinical hypothyroidism (SCH).
Methods We carried out a retrospective analysis on the clinical data of 264 patients with their first diagnosis of subclinical hypothyroidism without treatment from 2010 January to 2014 January. A total of 288 healthy controls were chosen from communities. The patients were groups based on TSH≥10.0 mU/L and 3.6 mU/L≤ TSH< 10.0 mU/L. We investigated the relationship between TSH and the level of blood lipids by analyzing liver and renal function, blood lipids, thyroid function, and thyroid peroxidase antibody (TPO-Ab) in the patients.
Results Triglyceride (TG) and high density lipoprotein cholesterol levels were not significantly different among the three groups (P>0.05). Total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels of the group with TSH≥10 mU/L were respectively (5.93±1.12) and (3.82±1.11) mmol/L, which were significantly higher than those in the controls[(4.43±1.12) and (2.66±0.43) mmol/L] (P<0.05). TC, TG and LDL-C levels of the group with 3.6 mU/L≤ TSH< 10.0 mU/L were higher than the controls, but the differences were not significant (P>0.05). After thyroid hormone replacement therapy within 12 weeks, TG, LDL-C, and TC levels of TPO-Ab positive patients with subclinical hypothyroidism (n=112) were respectively (4.62±1.03), (2.97±0.52), and (1.17±0.62) mmol/L, which were significantly lower than those levels before treatment[(5.43±1.18), (3.62±0.58), and (2.03±0.71) mmol/L] (P<0.05).
Conclusion The disorder of lipid metabolism exists in patients with subclinical hypothyroidism. Especially, the level of TSH greater than or equal to 10 mU/L is a high risk factor for dyslipidemia. In TPO-Ab positive patients, therapy of thyroid hormone replacement can effectively improve the blood lipid abnormalities in patients with subclinical hypothyroidism, and it may be an effective measure to improve the disorder of lipid metabolism economically and effectively.
Citation:
YEWen-chun, FANGXiang-ming, WANGYu-rong, GAOLi, HUANGJing. Study on the Relationship between Thyroid Stimulating Hormone and Lipid Profiles in Patients with Subclinical Hypothyroidism. West China Medical Journal, 2015, 30(5): 846-849. doi: 10.7507/1002-0179.20150244
Copy
Copyright © the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved
1. |
Oner FA, Yurdakul S, Oner E, et al. Evaluation of the effect of L-thyroxin therapy on cardiac functions by using novel tissue doppler-derived indices in patients with subclinical hypothyroidism[J]. Acta Cardiol, 2011, 66(1):47-55.
|
2. |
Rotondi M, Magri F, Chiovato L. Risk of coronary heart disease and mortality for adults with subclinical hypotyroidism[J]. JAMA, 2010, 304(22):2481-2482.
|
3. |
Tagami T, Tamanaha T, Shimazu S, et al. Lipid profiles in the untreated patients with Hashimoto thyroiditis and the effects of thyroxine treatment on subclinical hypothyroldism with Hashimoto thyroiditis[J]. Endocr J, 2010, 57(1):253-258.
|
4. |
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994):National Health and Nutrition Examination Survey (NHANES Ⅲ)[J]. J Clin Endocrinol Metab, 2002, 87(2):489-499.
|
5. |
Wang F, Tan Y, Wang C, et al. Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones[J]. J Clin Endocrinol Metab, 2012, 97(8):2724-2731.
|
6. |
Tian L, Song Y, Xing M, et al. A novel role for thyroid-stimulating hormone:up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway[J]. Hepatology, 2010, 52(4):1401-1409.
|
7. |
Monzani F, Del GP, Caraccio N, et al. Subclinical hypothyroidism:neurobehavioral features and beneficial effect of L-thyroxine treatment[J]. Clin Investig, 1993, 71(5):367-371.
|
8. |
张国峰. 左甲状腺素对甲状腺功能减退症及亚临床甲状腺功能减退症患者血脂的影响[J]. 中国全科医学, 2010, 13(7B):2213-2215.
|
9. |
董梅, 齐宝庆. 亚临床甲状腺功能减退症的研究进展[J]. 内科, 2008, 3(5):767.
|
- 1. Oner FA, Yurdakul S, Oner E, et al. Evaluation of the effect of L-thyroxin therapy on cardiac functions by using novel tissue doppler-derived indices in patients with subclinical hypothyroidism[J]. Acta Cardiol, 2011, 66(1):47-55.
- 2. Rotondi M, Magri F, Chiovato L. Risk of coronary heart disease and mortality for adults with subclinical hypotyroidism[J]. JAMA, 2010, 304(22):2481-2482.
- 3. Tagami T, Tamanaha T, Shimazu S, et al. Lipid profiles in the untreated patients with Hashimoto thyroiditis and the effects of thyroxine treatment on subclinical hypothyroldism with Hashimoto thyroiditis[J]. Endocr J, 2010, 57(1):253-258.
- 4. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994):National Health and Nutrition Examination Survey (NHANES Ⅲ)[J]. J Clin Endocrinol Metab, 2002, 87(2):489-499.
- 5. Wang F, Tan Y, Wang C, et al. Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones[J]. J Clin Endocrinol Metab, 2012, 97(8):2724-2731.
- 6. Tian L, Song Y, Xing M, et al. A novel role for thyroid-stimulating hormone:up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway[J]. Hepatology, 2010, 52(4):1401-1409.
- 7. Monzani F, Del GP, Caraccio N, et al. Subclinical hypothyroidism:neurobehavioral features and beneficial effect of L-thyroxine treatment[J]. Clin Investig, 1993, 71(5):367-371.
- 8. 张国峰. 左甲状腺素对甲状腺功能减退症及亚临床甲状腺功能减退症患者血脂的影响[J]. 中国全科医学, 2010, 13(7B):2213-2215.
- 9. 董梅, 齐宝庆. 亚临床甲状腺功能减退症的研究进展[J]. 内科, 2008, 3(5):767.
Journal type citation(11)
1. | 孙恒,邢作英,黄金雨,邱伯雍,王永霞. 参芍胶囊治疗冠心病心绞痛的Meta分析与试验序贯分析. 中国中药杂志. 2024(12): 3385-3395 . Baidu Scholar | |
2. | 郑惠灵,孙柯,陈惠,盖玉宁,郑喜灿. 负压封闭引流对开放性骨折创面影响的Meta分析及试验序贯分析. 中国烧伤创疡杂志. 2022(01): 33-38 . Baidu Scholar | |
3. | 扈晓靖,崔冰,高青,王志杰,刘玉楠. 百令胶囊改善维持性血液透析患者微炎症与营养状态的Meta分析. 中国中药杂志. 2022(09): 2547-2555 . Baidu Scholar | |
4. | 翁鸿,王颖,李柄辉,曾宪涛. 系统评价与Meta分析的类型及制作步骤. 同济大学学报(医学版). 2019(02): 248-253 . Baidu Scholar | |
5. | 李杰. 基于Meta分析的循证医学信息与数据处理方法. 科技创新导报. 2018(17): 146-147 . Baidu Scholar | |
6. | 桂裕亮,陈尊,田国祥,曾宪涛. 临床研究设计方案要点之临床试验方案设计的几点思考. 中国循证心血管医学杂志. 2017(06): 641-643 . Baidu Scholar | |
7. | 吴健瑜,孙伟鹏,郭惟,杨海淦,张子敬,侯政昆,樊冬梅,温俊茂,陈育忠. 镍钛记忆合金加压吻合夹在消化道吻合术中的系统评价及序贯分析. 中国组织工程研究. 2017(18): 2946-2952 . Baidu Scholar | |
8. | 翁鸿,郭成城,吕军,孟详喻,郭中强,曾宪涛. 试验序贯分析之信息量的计算. 中国循证医学杂志. 2017(01): 113-116 . Baidu Scholar | |
9. | 翁鸿,蔡林,吴开杰,方程,曾光,曾宪涛. 随机效应模型试验序贯分析中研究间方差估算方法的比较研究. 中国循证医学杂志. 2017(03): 369-372 . Baidu Scholar | |
10. | 翁鸿,李晓东,尹晓红,宁向辉,赵宇航,曾宪涛. 基于试验序贯分析检验Cochrane泌尿外科学组Meta分析假阴性结果. 中国循证医学杂志. 2017(05): 593-597 . Baidu Scholar | |
11. | 翁鸿,李胜,何发智,杨林,刘同族,曾宪涛. 试验序贯分析在Stata软件中的实现. 中国循证医学杂志. 2016(12): 1472-1476 . Baidu Scholar | |
Other types of references(4)
1. | 漆璐. 沙格列汀联合胰岛素治疗2型糖尿病有效性与安全性的Meta分析[D]. 吉林大学. 2017. Baidu Scholar | |
2. | 银子涵. 针刺干预遗忘型轻度认知障碍的临床疗效及对肠道微生物与代谢物的影响研究[D]. 成都中医药大学. 2024. Baidu Scholar | |
3. | 冷佳航. 复方甘草酸苷联合抗组胺药治疗慢性湿疹的Meta分析[D]. 辽宁中医药大学. 2018. Baidu Scholar | |
4. | 王蔚云. 慢性心力衰竭患者个体化液体摄入方案的构建与应用[D]. 南京医科大学. 2020. Baidu Scholar | |